about
Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasisUsing pharmacological chaperones to restore proteostasisCombining valosin-containing protein (VCP) inhibition and suberanilohydroxamic acid (SAHA) treatment additively enhances the folding, trafficking, and function of epilepsy-associated γ-aminobutyric acid, type A (GABAA) receptorsChemical and biological approaches synergize to ameliorate protein-folding diseases.Grp94 Protein Delivers γ-Aminobutyric Acid Type A (GABAA) Receptors to Hrd1 Protein-mediated Endoplasmic Reticulum-associated Degradation.Identification of GABA(C) receptor protein homeostasis network components from three tandem mass spectrometry proteomics approaches.SAHA enhances Proteostasis of epilepsy-associated α1(A322D)β2γ2 GABA(A) receptors.Proteostasis Maintenance of Cys-Loop Receptors.L-type Calcium Channel Blockers Enhance Trafficking and Function of Epilepsy-associated α1(D219N) Subunits of GABA(A) Receptors.FKBP10 depletion enhances glucocerebrosidase proteostasis in Gaucher disease fibroblasts.Endoplasmic reticulum Ca2+ increases enhance mutant glucocerebrosidase proteostasis.Different binding orientations for the same agonist at homologous receptors: a lock and key or a simple wedge?Remodeling the endoplasmic reticulum proteostasis network restores proteostasis of pathogenic GABAA receptorsLMAN1 (ERGIC-53) promotes trafficking of neuroreceptorsInteractome Changes Quantified to Identify the ER Proteostasis Network to Fight Amyloid Diseases
P50
Q28472162-89162B9B-422B-447C-9ED4-6A77218B13ABQ33804655-22D2EF37-4633-4EEC-953C-CBF41D6EB40EQ34801457-27A39142-4D98-4AE5-8DE8-AC50B814B052Q34822475-A5756E95-6133-4152-91BC-422BA7E9CE78Q36850007-F4CE4222-B31A-448D-86BD-80555DF3A1DBQ37394642-4EDA5A7F-0DF6-406D-8355-95E33B05C9BEQ37412871-B98AD092-3E55-4AC0-BBE6-625A76C36A16Q38752299-C3F6B3C2-7E62-4E1D-B09E-8D12A6977B22Q38853747-1C578D5A-5759-4650-B4F1-9C6A2DB5514BQ39190061-BB360492-4020-4F8D-BCC2-09EBE52D329CQ41976836-B4F68C24-6302-4975-9400-36F5D3B38FFBQ44463600-74288E5D-0F62-42E7-9AEB-EEECE7B96F4BQ59807946-A934566E-1709-4D83-B612-046676EA71A8Q91811743-517095BD-BDA4-4405-97E1-375A73661A27Q92022811-8020F6BC-9DDD-4FE7-B135-0A80593A7808
P50
description
researcher
@en
name
Ting-Wei Mu
@en
Ting-Wei Mu
@nl
type
label
Ting-Wei Mu
@en
Ting-Wei Mu
@nl
prefLabel
Ting-Wei Mu
@en
Ting-Wei Mu
@nl
P108
P106
P31
P496
0000-0002-6419-9296